Long COVID involves activation of proinflammatory and immune exhaustion pathways

/in , ,

Aid M, Boero-Teyssier V, McMahan K, Dang R, Doyle M, Belabbaci N, Borducchi E, Collier AY, Mullington J, Barouch DH. Long COVID involves activation of proinflammatory and immune exhaustion pathways. Nat Immunol. 2026 Jan;27(1):61-71. doi: 10.1038/s41590-025-02353-x. Epub 2025 Dec 12. Erratum in: Nat Immunol. 2026 Jan 23. doi: 10.1038/s41590-026-02438-1. PMID: 41388153; PMCID: PMC12764429.

Anti-IL-15 treatment reduces acute lentivirus inflammation and signaling in the brain

/in , ,

Ram DR, Gopalakrishnan RM, Aid M, Kroll K, Miftahof J, Aristizabal O, Gikundiro EK, Davis C, Hefti MM, Fiock KL, Tilahun B, Umutoniwase Y, Loidolt K, Fennessey CM, Mercado NB, Harper-Alexander V, Jones R, Woolley G, Varner V, Lifton M, Bosinger SE, Barouch DH, Keele BF, Reeves RK, Tan CS. Anti-IL-15 treatment reduces acute lentivirus inflammation and signaling in the brain. Cell Rep Med. 2026 Jan 20;7(1):102567. doi: 10.1016/j.xcrm.2025.102567

Associations between the microbiome and immune responses to an adenovirus-based HIV-1 candidate vaccine are distinct between African and US cohorts

/in

Li Y, Stieh DJ, Droit L, Kim AH, Rodgers R, Mihindukulasuriya KA, Wang L, Pau MG, Yuan O, Virgin HW, Barouch DH, Baldridge MT, Handley SA. Associations between the microbiome and immune responses to an adenovirus-based HIV-1 candidate vaccine are distinct between African and US cohorts. mSystems. 2026 Jan 15:e0143525. doi: 10.1128/msystems.01435-25. Epub ahead of print. PMID: 41537600.

Development and validation of HIV SMRTcap for the characterization of HIV-1 reservoirs across tissues and subtypes

/in

Sadri G, Nadakal ST, Lauer W, Kos J, Singh PK, Elliott E, Kaiser CW, Ford EE, Richardson N, Shields KM, Hudson E, Linden NL, Danesh A, Powell J, Warburton P, Soto J, Emery M, Deikus G, Lee GQ, Lamers SL, Reynolds SJ, Galiwango R, Prodger JL, Tomusange S, Kityamuweesi T, Han T, Jones RB, Tobian AAR, Engelman AN, Sebra R, Morgello S, Redd AD, Sachs D, Rouchka E, Smith ML. Development and validation of HIV SMRTcap for the characterization of HIV-1 reservoirs across tissues and subtypes. PLoS Pathog. 2026 Jan 13;22(1):e1013171. doi: 10.1371/journal.ppat.1013171. PMID: 41529060; PMCID: PMC12851485.

Immunogenicity of JN.1 and KP.2 COVID-19 mRNA vaccines against emerging SARS-CoV-2 variants

/in

Lasrado N, Rössler A, McConnell I, Molloy K, Bhowmik R, Happle C, Guan R, McMahan K, Pereira J, Liu J, Borducchi E, Wang L, Shah K, Wixted B, Stankov MV, Dopfer-Jablonka A, Collier AY, Behrens GMN, Barouch DH. Immunogenicity of JN.1 and KP.2 COVID-19 mRNA vaccines against emerging SARS-CoV-2 variants. Vaccine. 2026 Jan 1;69:127997. doi: 10.1016/j.vaccine.2025.127997. Epub 2025 Nov 19. PMID: 41265004; PMCID: PMC12643176.

Application of a novel branched-DNA assay to quantify killer immunoglobulin-like receptor (KIR) mRNA expression identifies tissue compartmentalization in naïve and SIV-infected rhesus macaques

/in

Terry K, Kroll KW, Jones RA, Reeves RK. Application of a novel branched-DNA assay to quantify killer immunoglobulin-like receptor (KIR) mRNA expression identifies tissue compartmentalization in naïve and SIV-infected rhesus macaques. J Immunol Methods. 2026 Jan;546:114022. doi: 10.1016/j.jim.2025.114022. Epub 2025 Dec 20. PMID: 41429386; PMCID: PMC12840321.

Minor SHIV variants abrogate protective efficacy of broadly neutralizing antibodies in rhesus macaques

/in ,

Walker-Sperling VEK, Nkolola J, Liu J, Aid M, Julg B, Seaman MS, Barouch DH. Minor SHIV variants abrogate protective efficacy of broadly neutralizing antibodies in rhesus macaques. Nat Commun. 2025 Dec 18;16(1):11226. doi: 10.1038/s41467-025-66321-7. PMID: 41413011; PMCID: PMC12714793.

Hydrogel formulations for sustained-release of broadly neutralizing antibodies

/in

Jons CK, Kasse CM, Mayer BT, Hyrien O, Sen S, Meany EL, d’Aquino AI, Ganesh P, Eckman N, Dong C, Yan J, Nguyen LT, Doulames VM, Song YE, Saouaf OM, Williams CM, Williams SC, Paredes J, Raghavan R, Palomares M, Alpert M, Yates NL, Tomaras GD, Seaman MS, Farzan M, Appel EA. Hydrogel formulations for sustained-release of broadly neutralizing antibodies. J Control Release. 2025 Dec 10;388(Pt 2):114349. doi: 10.1016/j.jconrel.2025.114349. Epub 2025 Oct 31. PMID: 41177463; PMCID: PMC12659352.

Stabilizers, Silencers, and Disease Stage: Lessons From Recent Trials of ATTR Cardiac Amyloidosis

/in

Siddiqi HK, Bhatt K, Gopal DM, Siddiqi OK. Stabilizers, Silencers, and Disease Stage: Lessons From Recent Trials of ATTR Cardiac Amyloidosis. J Am Coll Cardiol. 2025 Dec 3:S0735-1097(25)09918-8. doi: 10.1016/j.jacc.2025.10.019. Epub ahead of print. PMID: 41335083.

Reflections on Advances in Cancer Research in 2025

/in

Bernard E, Cortés-Ciriano I, Gaiti F, Gan S, Jiang S, Kovatcheva M, Meisel M, Reticker-Flynn NE, Schram AM, Shoshani O, Silverbush D, Venkataramani V, Weeden CE, Zhou X. Reflections on Advances in Cancer Research in 2025. Cancer Discov. 2025 Dec 2;15(12):2422-2430. doi: 10.1158/2159-8290.CD-25-1833. PMID: 41327969.